How Is IVIG Used for Immune-Mediated Necrotizing Myopathy?

IVIG, or Intravenous Immunoglobulin, is an immunomodulatory treatment frequently used for immune-mediated necrotizing myopathy (IMNM). It involves infusing a concentrated preparation of antibodies (immunoglobulins) pooled from the plasma of thousands of healthy blood donors ^[1]. In autoimmune conditions like IMNM, IVIG is given in high doses to help regulate the immune system and reduce muscle damage ^[1][2]. It is often used alongside corticosteroids or other immunosuppressants, though it is sometimes considered as an early or primary therapy in specific situations, such as severe disease, difficulty swallowing, or certain anti-HMGCR cases ^[3][2].

How IVIG is Proposed to Work in IMNM

In IMNM, the immune system mistakenly produces harmful autoantibodies (such as anti-HMGCR or anti-SRP) that contribute to muscle fiber destruction (necrosis) ^[4]. While the exact mechanisms are still being studied, researchers propose that IVIG may reduce this damage in several ways:

1. Interacting with Autoantibodies

IVIG contains a vast array of donor antibodies. It is hypothesized that some of these donor antibodies can bind to and neutralize the harmful autoantibodies driving IMNM ^[5][6]. Additionally, providing the body with a high dose of immunoglobulins may saturate certain receptors, potentially accelerating the clearance of the patient’s own harmful autoantibodies ^[6][7].

2. Reducing Complement-Mediated Injury

When autoantibodies attack muscle tissue, they can activate the complement cascade—an immune process that can lead to the formation of a membrane attack complex (MAC) ^[8]. MAC can damage muscle-cell membranes, contributing to muscle necrosis ^[4]. IVIG may help inhibit this complement cascade, potentially reducing this specific type of muscle injury ^[9][7]. It is important to note that complement activation is only one part of IMNM biology, and IVIG has multiple complex effects on immune cells.

The Treatment Process and Clinical Evidence

IVIG therapy requires a significant time and financial commitment. An initial treatment course is typically divided over several consecutive days, with each infusion taking several hours ^[10]. Depending on your response, maintenance doses may be given every few weeks ^[10]. Dosing is highly individualized based on your body weight, kidney function, and medical history.

Most evidence supporting IVIG in IMNM comes from observational studies and clinical experience rather than large randomized trials ^[11][12]. These studies suggest that IVIG can lower creatine kinase (CK) levels (a marker of muscle breakdown) and may improve muscle strength, particularly in patients with the anti-HMGCR subtype ^[11][12]. However, treatment response varies. It is common for CK levels to drop before noticeable improvements in functional strength (like climbing stairs) occur ^[12]. For the anti-SRP subtype, combination therapy (such as steroids and rituximab) is often required rather than IVIG alone ^[3][13]. Relapses can occur if infusions are spaced out or stopped, so any changes must be carefully managed by your specialist ^[14].

Safety, Side Effects, and Monitoring

Because IVIG is a complex biological product given in high doses, it requires careful monitoring ^[15]. Before starting, tell your clinical team if you have kidney disease, a history of blood clots, heart disease, dehydration, or previous reactions to immunoglobulin products.

Common infusion effects: You may experience headache, chills, fever, nausea, fatigue, or flushing during or shortly after the infusion ^[16]. Your team may provide premedications (like antihistamines or pain relievers) or slow the infusion rate to minimize these effects ^[15].

Serious risks and red flags: Though uncommon, IVIG can cause severe complications, including aseptic meningitis (brain lining inflammation), severe allergic reactions (anaphylaxis), blood clots (thrombosis), kidney injury, fluid overload, and hemolysis (red blood cell breakdown) ^[16][15].

Seek urgent medical care if you experience any of the following during or after treatment:

• Severe, persistent headache with neck stiffness, light sensitivity, confusion, or vomiting.
• Chest pain, shortness of breath, or new trouble breathing.
• Swelling in one leg, or facial/throat swelling.
• Markedly reduced urination, dark urine, or yellowing of the skin/eyes (jaundice).
• Rapidly worsening muscle weakness or new difficulty swallowing or choking.